BIO Europe: How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms
Summary: As the global pandemic began to spread, the Catalent global network quickly pivoted to support over 50 COVID-related antiviral, vaccine, diagnostic and treatment programs across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. Hear from Mario Gargiulo, Catalent’s Region President, Biologics, Europe in this fireside chat interview with Dan Stanton, Editor and Founder, Bioprocess Insider.